U.S. Markets close in 4 hrs 5 mins

Genocea Biosciences, Inc. (GNCA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1400-0.1200 (-5.31%)
As of 11:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2600
Open2.2400
Bid2.1400 x 1200
Ask2.1700 x 800
Day's Range2.1200 - 2.2600
52 Week Range1.1000 - 5.7500
Volume90,140
Avg. Volume729,293
Market Cap109.901M
Beta (5Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-1.4690
Earnings DateOct 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.40
  • Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast
    GlobeNewswire

    Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

    CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.About Genocea Biosciences, Inc. Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.Investor Contact: Dan Ferry 617-430-7576 daniel@lifesciadvisors.com

  • Does Genocea Biosciences' (NASDAQ:GNCA) CEO Salary Compare Well With Industry Peers?
    Simply Wall St.

    Does Genocea Biosciences' (NASDAQ:GNCA) CEO Salary Compare Well With Industry Peers?

    This article will reflect on the compensation paid to Chip Clark who has served as CEO of Genocea Biosciences, Inc...

  • Is Genocea Biosciences (GNCA) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Genocea Biosciences (GNCA) Stock Outpacing Its Medical Peers This Year?

    Is (GNCA) Outperforming Other Medical Stocks This Year?